These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 22301383)

  • 21. Clinical utility of probiotics in inflammatory bowel disease.
    Cain AM; Karpa KD
    Altern Ther Health Med; 2011; 17(1):72-9. PubMed ID: 21614946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy.
    Mileti E; Matteoli G; Iliev ID; Rescigno M
    PLoS One; 2009 Sep; 4(9):e7056. PubMed ID: 19756155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease.
    Gironella M; Iovanna JL; Sans M; Gil F; Peñalva M; Closa D; Miquel R; Piqué JM; Panés J
    Gut; 2005 Sep; 54(9):1244-53. PubMed ID: 15870231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease.
    Selvam R; Maheswari P; Kavitha P; Ravichandran M; Sas B; Ramchand CN
    Indian J Biochem Biophys; 2009 Feb; 46(1):79-85. PubMed ID: 19374258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammatory bowel disease, gut bacteria and probiotic therapy.
    Reiff C; Kelly D
    Int J Med Microbiol; 2010 Jan; 300(1):25-33. PubMed ID: 19800289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment.
    Veltkamp C; Anstaett M; Wahl K; Möller S; Gangl S; Bachmann O; Hardtke-Wolenski M; Länger F; Stremmel W; Manns MP; Schulze-Osthoff K; Bantel H
    Gut; 2011 Oct; 60(10):1345-53. PubMed ID: 21459928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance.
    Caradonna L; Amati L; Magrone T; Pellegrino NM; Jirillo E; Caccavo D
    J Endotoxin Res; 2000; 6(3):205-14. PubMed ID: 11052175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial effect of immunobiotic strains on attenuation of Salmonella induced inflammatory response in human intestinal epithelial cells.
    Kanmani P; Kim H
    PLoS One; 2020; 15(3):e0229647. PubMed ID: 32150574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases.
    Vanderpool C; Yan F; Polk DB
    Inflamm Bowel Dis; 2008 Nov; 14(11):1585-96. PubMed ID: 18623173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gut immune stimulation by non pathogenic Gram(+) and Gram(-) bacteria. Comparison with a probiotic strain.
    Dogi CA; Galdeano CM; Perdigón G
    Cytokine; 2008 Mar; 41(3):223-31. PubMed ID: 18248820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?
    Seksik P; Dray X; Sokol H; Marteau P
    Mol Nutr Food Res; 2008 Aug; 52(8):906-12. PubMed ID: 18384087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease.
    Shanahan F
    Am J Physiol Gastrointest Liver Physiol; 2005 Mar; 288(3):G417-21. PubMed ID: 15701620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics.
    Geier MS; Butler RN; Howarth GS
    Int J Food Microbiol; 2007 Apr; 115(1):1-11. PubMed ID: 17137666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probiotics and inflammatory bowel diseases.
    Bai AP; Ouyang Q
    Postgrad Med J; 2006 Jun; 82(968):376-82. PubMed ID: 16754706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Probiotics: history, definition, requirements and possible therapeutic applications].
    Montalto M; Arancio F; Izzi D; Cuoco L; Curigliano V; Manna R; Gasbarrini G
    Ann Ital Med Int; 2002; 17(3):157-65. PubMed ID: 12402663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probiotics in experimental and human inflammatory bowel disease: discussion points.
    Pagnini C; Cominelli F
    Dig Liver Dis; 2006 Dec; 38 Suppl 2():S270-3. PubMed ID: 17259089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of selected Lactobacillus and Bifidobacterium species on Listeria monocytogenes infection and the mucosal immune response.
    Corr SC; Gahan CG; Hill C
    FEMS Immunol Med Microbiol; 2007 Aug; 50(3):380-8. PubMed ID: 17537177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical evidence for immunomodulatory effects of probiotic bacteria.
    Ruemmele FM; Bier D; Marteau P; Rechkemmer G; Bourdet-Sicard R; Walker WA; Goulet O
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):126-41. PubMed ID: 19179874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intestinal microflora and homeostasis of the mucosal immune response: implications for probiotic bacteria?
    Blum S; Schiffrin EJ
    Curr Issues Intest Microbiol; 2003 Sep; 4(2):53-60. PubMed ID: 14503689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production.
    Candela M; Perna F; Carnevali P; Vitali B; Ciati R; Gionchetti P; Rizzello F; Campieri M; Brigidi P
    Int J Food Microbiol; 2008 Jul; 125(3):286-92. PubMed ID: 18524406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.